Canada · Delayed Price · Currency is CAD CareRx Earnings Call Transcripts
Fiscal Year 2026
-
Q3 revenue rose 2.2% YoY to CAD 95.3 million, while adjusted EBITDA was CAD 8.1 million and net income CAD 240,000. Approximately 3,000 new beds were onboarded; Q4 should capture their full-quarter contribution, with higher fuel costs remaining a headwind.
-
Q2 2026 saw stable revenue and EBITDA, with net income impacted by Ontario ward bed funding changes. A major contract win will add 3,000 retirement beds in Q3, supporting growth targets. Dividend was raised 10%, and margin benefits from generics are expected in 2027.
-
Q1 2026 saw strong revenue and margin growth, driven by new beds and efficiency gains. Ontario's funding stability supports long-term outlook, though removal of ward bed funding may reduce fees by up to CAD 2 million. Generic semaglutide launch expected to benefit margins in 2027.
Fiscal Year 2025
-
Q4 2025 saw strong revenue and margin growth, with full-year net income positive for the first time. Bed count and operational efficiency improved, leverage declined, and capital returns to shareholders increased. Outlook targets further bed growth and margin expansion.
-
Q3 2025 saw revenue of CAD 93.2M, Adjusted EBITDA of CAD 8.3M, and net income of CAD 1.6M, with margin expansion and strong cash flow. Bed growth and efficiency initiatives support a positive outlook, with robust organic and M&A opportunities ahead.
-
Q2 2025 revenue was $91.4M, with adjusted EBITDA up 7% year-over-year and net income of $561K. 3,000 new beds were onboarded, supporting growth targets and margin expansion, while capital allocation remains focused on bed growth, efficiency, and share buybacks.
-
Revenue and adjusted EBITDA remained stable year-over-year, with net income turning positive. Operational efficiencies, new bed wins, and the Burnaby consolidation are expected to drive further growth and margin improvements in 2025.
Fiscal Year 2024
-
Q4 2024 saw revenue and adjusted EBITDA growth year-over-year, with improved cash flow and a reduced net loss. Debt restructuring and operational efficiencies position the company for robust bed growth and margin expansion in 2025.
-
Q3 2024 saw revenue of CAD 92.8 million and adjusted EBITDA of CAD 7.8 million, with margins and net loss improving year-over-year. Operational efficiencies, debt reduction, and a new fulfillment center support a robust growth outlook, with nearly 3,000 new beds secured for 2025.
-
Q2 2024 saw revenue of CAD 92M and adjusted EBITDA of CAD 7.5M, with margin improvements from operational efficiencies and a new supply agreement. Net loss was CAD 1.4M due to non-cash items. Growth is expected in H2 2024, with stable margins and a robust pipeline.